2026 Q3 - tulosraportti
9 päivää sitten
‧36 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.3.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 10.11. | ||
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 12.3. | ||
2025 Q3 - tulosraportti 10.11.2025 |
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·6.10.Watch out out there - it is not a bulletproof approval. A quick AI test (remember to fact-check yourself and remember AI can be wrong either way): ------------------------------ The challenges and data in the clinical development for deramiocel are detailed below: 1. The clinical results (HOPE-3 study) In the Phase 3 study itself (HOPE-3), which covered 106 patients, Capricor met their primary endpoint: • Muscle function: The treatment slowed the decline in upper body function (measured via the PUL 2.0 scale) by 54% to 76% compared to placebo. This meant that patients maintained vital functions in arms and hands significantly longer. • Heart function: Measurable improvements in the heart's pumping capacity (LVEF) and reduced scarring in the heart muscle were observed. The data were even published in the renowned medical journal The Lancet. 2. Why is there so much doubt about the approval? Although the results sound convincing on paper, the company met a massive wall with the US health authorities (FDA). During an external advisory expert panel meeting (Advisory Committee) at FDA, the panel voted 9 to 3 against recommending deramiocel for approval. The reasons were critical: • Statistical disagreement: FDA's own reviewers accused Capricor of having changed their statistical analysis plan (SAP) very late in the process to make the data look better. • Blinding breach: FDA raised doubts about whether the trial was genuinely "double-blind", because the side effects (such as hypersensitivity reactions) were markedly different in the treatment group than in the placebo group, which could have revealed who received the medicine. • Conclusion: FDA stated directly that they did not believe the company had provided sufficient evidence of the drug's real efficacy. 3. What is the current status? Following the negative panel meeting, Capricor faced an almost certain rejection in August. However, in the eleventh hour, the company managed to submit a major amendment to their application with new 24-month data. FDA agreed to look at the new data, which has pushed the timeline and the final decision (the PDUFA date). 4. The price targets are unadjusted "if-scenarios" When an equity research firm like H.C. Wainwright maintains or issues very high price targets in biotech, they often calculate the company's value under the assumption that the product comes to market (a so-called unrisked or low-risk-adjusted scenario). That the market and other analysts are deeply skeptical was seen recently when the stock fell despite the company presenting new positive data. A number of skeptical analysts continue to expect that FDA will end up issuing a regular rejection (a so-called Complete Response Letter or CRL). Summary The probability of an approval is not generally assessed as high in the market - on the contrary, it is fraught with enormous regulatory risk due to FDA's skepticism. The price target of $60 exclusively reflects the gigantic potential if the company miraculously manages to convince FDA with their latest data package. Would you like me to investigate the exact new date for FDA's decision, or would you like to take a closer look at the company's current cash reserves to see how long they can survive without an approval?They have started posting job ads again and want to hire . So I wonder if something is on the way ?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
9 päivää sitten
‧36 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·6.10.Watch out out there - it is not a bulletproof approval. A quick AI test (remember to fact-check yourself and remember AI can be wrong either way): ------------------------------ The challenges and data in the clinical development for deramiocel are detailed below: 1. The clinical results (HOPE-3 study) In the Phase 3 study itself (HOPE-3), which covered 106 patients, Capricor met their primary endpoint: • Muscle function: The treatment slowed the decline in upper body function (measured via the PUL 2.0 scale) by 54% to 76% compared to placebo. This meant that patients maintained vital functions in arms and hands significantly longer. • Heart function: Measurable improvements in the heart's pumping capacity (LVEF) and reduced scarring in the heart muscle were observed. The data were even published in the renowned medical journal The Lancet. 2. Why is there so much doubt about the approval? Although the results sound convincing on paper, the company met a massive wall with the US health authorities (FDA). During an external advisory expert panel meeting (Advisory Committee) at FDA, the panel voted 9 to 3 against recommending deramiocel for approval. The reasons were critical: • Statistical disagreement: FDA's own reviewers accused Capricor of having changed their statistical analysis plan (SAP) very late in the process to make the data look better. • Blinding breach: FDA raised doubts about whether the trial was genuinely "double-blind", because the side effects (such as hypersensitivity reactions) were markedly different in the treatment group than in the placebo group, which could have revealed who received the medicine. • Conclusion: FDA stated directly that they did not believe the company had provided sufficient evidence of the drug's real efficacy. 3. What is the current status? Following the negative panel meeting, Capricor faced an almost certain rejection in August. However, in the eleventh hour, the company managed to submit a major amendment to their application with new 24-month data. FDA agreed to look at the new data, which has pushed the timeline and the final decision (the PDUFA date). 4. The price targets are unadjusted "if-scenarios" When an equity research firm like H.C. Wainwright maintains or issues very high price targets in biotech, they often calculate the company's value under the assumption that the product comes to market (a so-called unrisked or low-risk-adjusted scenario). That the market and other analysts are deeply skeptical was seen recently when the stock fell despite the company presenting new positive data. A number of skeptical analysts continue to expect that FDA will end up issuing a regular rejection (a so-called Complete Response Letter or CRL). Summary The probability of an approval is not generally assessed as high in the market - on the contrary, it is fraught with enormous regulatory risk due to FDA's skepticism. The price target of $60 exclusively reflects the gigantic potential if the company miraculously manages to convince FDA with their latest data package. Would you like me to investigate the exact new date for FDA's decision, or would you like to take a closer look at the company's current cash reserves to see how long they can survive without an approval?They have started posting job ads again and want to hire . So I wonder if something is on the way ?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.3.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 10.11. | ||
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 12.3. | ||
2025 Q3 - tulosraportti 10.11.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
9 päivää sitten
‧36 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.3.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 10.11. | ||
2026 Q2 - tulosraportti 13.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 12.3. | ||
2025 Q3 - tulosraportti 10.11.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·6.10.Watch out out there - it is not a bulletproof approval. A quick AI test (remember to fact-check yourself and remember AI can be wrong either way): ------------------------------ The challenges and data in the clinical development for deramiocel are detailed below: 1. The clinical results (HOPE-3 study) In the Phase 3 study itself (HOPE-3), which covered 106 patients, Capricor met their primary endpoint: • Muscle function: The treatment slowed the decline in upper body function (measured via the PUL 2.0 scale) by 54% to 76% compared to placebo. This meant that patients maintained vital functions in arms and hands significantly longer. • Heart function: Measurable improvements in the heart's pumping capacity (LVEF) and reduced scarring in the heart muscle were observed. The data were even published in the renowned medical journal The Lancet. 2. Why is there so much doubt about the approval? Although the results sound convincing on paper, the company met a massive wall with the US health authorities (FDA). During an external advisory expert panel meeting (Advisory Committee) at FDA, the panel voted 9 to 3 against recommending deramiocel for approval. The reasons were critical: • Statistical disagreement: FDA's own reviewers accused Capricor of having changed their statistical analysis plan (SAP) very late in the process to make the data look better. • Blinding breach: FDA raised doubts about whether the trial was genuinely "double-blind", because the side effects (such as hypersensitivity reactions) were markedly different in the treatment group than in the placebo group, which could have revealed who received the medicine. • Conclusion: FDA stated directly that they did not believe the company had provided sufficient evidence of the drug's real efficacy. 3. What is the current status? Following the negative panel meeting, Capricor faced an almost certain rejection in August. However, in the eleventh hour, the company managed to submit a major amendment to their application with new 24-month data. FDA agreed to look at the new data, which has pushed the timeline and the final decision (the PDUFA date). 4. The price targets are unadjusted "if-scenarios" When an equity research firm like H.C. Wainwright maintains or issues very high price targets in biotech, they often calculate the company's value under the assumption that the product comes to market (a so-called unrisked or low-risk-adjusted scenario). That the market and other analysts are deeply skeptical was seen recently when the stock fell despite the company presenting new positive data. A number of skeptical analysts continue to expect that FDA will end up issuing a regular rejection (a so-called Complete Response Letter or CRL). Summary The probability of an approval is not generally assessed as high in the market - on the contrary, it is fraught with enormous regulatory risk due to FDA's skepticism. The price target of $60 exclusively reflects the gigantic potential if the company miraculously manages to convince FDA with their latest data package. Would you like me to investigate the exact new date for FDA's decision, or would you like to take a closer look at the company's current cash reserves to see how long they can survive without an approval?They have started posting job ads again and want to hire . So I wonder if something is on the way ?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt






